BioMarin Pharmaceutical has struck a deal to purchase fellow biotechnology firm Amicus Therapeutics for about $4.8 billion in money.
Source link
BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion
Related Posts
AI Costs Continue to Rise Despite Falling Token Prices
Falling token costs have not lowered enterprise AI payments. As organizations broaden agentic AI and course of extra information, hidden…
Digital Twins and the Risks of AI Immortality
AI digital twins are turning into autonomous brokers that act for us — elevating critical dangers round id, management, and…
SpaceX needs to achieve 2 of its moonshots to keep valuation: Steve Westly
SpaceX workers go to work on the SpaceX facility in Hawthorne on the day of their firm’s IPO, in Hawthorne,…